Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

References

• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, Phase 3 trial. Lancet Oncol. 2019;20:1506–1517. doi:10.1016/S1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–1203. doi:10.1056/NEJMoa2032125
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449–462. doi:10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, Phase 2 trial. Lancet Oncol. 2017;18:631–639. doi:10.1016/S1470-2045(17)30181-X
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee KH, Kang J, et al. Hyperprogressive disease during anti-PD-1 (PDCD1)/PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers. 2019;11:1699. doi:10.3390/cancers11111699
   PubMed Web of Science ®Google Scholar
• Toki MI, Syrigos N, Syrigos K. Hyperprogressive disease: a distinct pattern of progression to immune checkpoint inhibitors. Int J Cancer. 2021;149:277–286. doi:10.1002/ijc.33429
   PubMed Web of Science ®Google Scholar
• Leone AG, Petrelli F, Ghidini A, Raimondi A, Smyth EC, Pietrantonio F. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score. ESMO Open. 2022;7:100380. doi:10.1016/j.esmoop.2021.100380
   PubMed Web of Science ®Google Scholar
• Yoon HH, Jin Z, Kour O, et al. Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol. 2022;8:1456–1465. doi:10.1001/jamaoncol.2022.3707
   PubMed Web of Science ®Google Scholar
• Shiraishi T, Toyozumi T, Sakata H, et al. Soluble PD-L1 concentration is proportional to the expression of PD-L1 in tissue and is associated with a poor prognosis in esophageal squamous cell carcinoma. Oncology. 2022;100:39–47. doi:10.1159/000518740
   PubMedGoogle Scholar
• Okadome K, Baba Y, Nomoto D, et al. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers. Br J Cancer. 2020;122:1535–1543. doi:10.1038/s41416-020-0811-0
   PubMed Web of Science ®Google Scholar
• Ota Y, Takahari D, Suzuki T, et al. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol. 2020;85:265–272. doi:10.1007/s00280-019-04023-w
   PubMed Web of Science ®Google Scholar
• Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018;11:955–965. doi:10.2147/OTT.S153290
   PubMed Web of Science ®Google Scholar
• Takenaka Y, Oya R, Takemoto N, Inohara H. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: meta-analysis. Head Neck. 2022;44:1237–1245. doi:10.1002/hed.26997
   PubMed Web of Science ®Google Scholar
• Sekine K, Kanda S, Goto Y, et al. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer. 2018;124:179–188. doi:10.1016/j.lungcan.2018.08.012
   PubMed Web of Science ®Google Scholar
• Xiao L, Li L, Chen G, Zhang Y, Gao Q. The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer. Transl Cancer Res. 2020;9:4111–4120. doi:10.21037/tcr-20-1451
   PubMed Web of Science ®Google Scholar
• Zhou K, Cao J, Lin H, et al. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: a systematic review and meta-analysis. Front Oncol. 2022;12:962173. doi:10.3389/fonc.2022.962173
   PubMed Web of Science ®Google Scholar
• Kurashina R, Ando K, Inoue M, et al. Platelet-to-lymphocyte ratio predicts the efficacy of pembrolizumab in patients with urothelial carcinoma. Anticancer Res. 2022;42:1131–1136. doi:10.21873/anticanres.15576
   PubMed Web of Science ®Google Scholar
• Cheng M, Li G, Liu Z, Yang Q, Jiang Y. Pretreatment neutrophil-to-lymphocyte ratio and lactate dehydrogenase predict the prognosis of metastatic cervical cancer treated with combination immunotherapy. J Oncol. 2022;2022:1828473. doi:10.1155/2022/1828473
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Takahashi M, Kato K, Okada M, et al. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). Esophagus. 2021;18:90–99. doi:10.1007/s10388-020-00794-x
   PubMed Web of Science ®Google Scholar
• Bonavita E, Galdiero MR, Jaillon S, Mantovani A. Phagocytes as corrupted policemen in cancer-related inflammation. Adv Cancer Res. 2015;128:141–171.
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283–287. doi:10.1023/B:AGEN.0000029415.62384.ba
   PubMedGoogle Scholar
• Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res. 2015;2015:983698. doi:10.1155/2015/983698
   PubMed Web of Science ®Google Scholar
• Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14:173. doi:10.1186/s13045-021-01187-y
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6:1670–1690. doi:10.3390/cancers6031670
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang Z, Li Y, et al. Pretreatment neutrophil-to-lymphocyte ratio as a prognostic biomarker in unresectable or metastatic esophageal cancer patients with anti-PD-1 therapy. Front Oncol. 2022;12:834564. doi:10.3389/fonc.2022.834564
   PubMed Web of Science ®Google Scholar
• Booka E, Kikuchi H, Haneda R, et al. Neutrophil-to-lymphocyte ratio to predict the efficacy of immune checkpoint inhibitor in upper gastrointestinal cancer. Anticancer Res. 2022;42:2977–2987. doi:10.21873/anticanres.15781
   PubMed Web of Science ®Google Scholar
• Liu J, Gao D, Li J, Hu G, Liu J, Liu D. The predictive value of systemic inflammatory factors in advanced, metastatic esophageal squamous cell carcinoma patients treated with camrelizumab. Onco Targets Ther. 2022;15:1161–1170. doi:10.2147/OTT.S382967
   PubMed Web of Science ®Google Scholar
• Zhang X, Gari A, Li M, et al. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma. J Transl Med. 2022;20:61. doi:10.1186/s12967-022-03252-7
   PubMed Web of Science ®Google Scholar